Stroke Outcomes in the COMPASS Trial

Circulation

139, 1134-1145

DOI: 10.1161/circulationaha.118.035864

Citation Report

#	Article	IF	Citations
1	Role of Oral Anticoagulant Therapy for Secondary Prevention in Patients With Stable Atherothrombotic Disease Manifestations. Therapeutic Advances in Hematology, 2019, 10, 2040620719861475.	2.8	5
2	Rivaroxaban Plus Aspirin for Cardiovascular Protection: Rationale for the Vascular Dose and Dual Pathway Inhibition. Thrombosis Research, 2019, 184, 44-49.	2.9	9
3	The Continuous Challenge of Antithrombotic Strategies in Diabetes: Focus on Direct Oral Anticoagulants. Acta Diabetologica, 2019, 56, 1247-1258.	3.8	7
4	Antithrombotic Therapy for Stroke Prevention. Circulation, 2019, 139, 1131-1133.	24.6	9
5	Prasugrel or Clopidogrel for Long-Term Secondary Stroke Prevention?. Lancet Neurology, The, 2019, 18, 222-223.	43.7	1
6	Dual-Pathway-Inhibition Bei Atherosklerose – Wer Profitiert?. Deutsche Medizinische Wochenschrift, 2019, 144, 1384-1389.	0.3	2
7	Patients at High Risk for Stroke Benefit From Combination Rivaroxaban Plus Aspirin in International Trial. Neurology Today: an Official Publication of the American Academy of Neurology, 2019, 19, 10.	0.0	0
8	Antithrombotic Management of Ischemic Stroke. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 1-15.	1.3	12
9	Accelerated Risk of Premature Ischemic Stroke in 5-Year Survivors of Nasopharyngeal Carcinoma. Oncologist, 2019, 24, e891-e897.	5.0	27
10	Cardiovascular Care of Patients With Stroke and High Risk of Stroke: The Need for Interdisciplinary Action: A Consensus Report From the European Society of Cardiology Cardiovascular Round Table. European Journal of Preventive Cardiology, 2020, 27, 682-692.	6.1	23
11	The SAPPHIRE Criteria, History of Myocardial Infarction and Diabetes Predict Adverse Outcomes Following Carotid Endarterectomy Similar to Stenting. Clinical Research in Cardiology, 2020, 109, 589-598.	3.9	7
12	Risk of First Stroke in People With Type 2 Diabetes and Its Relation to Glycaemic Control: A Nationwide Observational Study. Diabetes, Obesity and Metabolism, 2020, 22, 182-190.	6.0	41
13	Atrial Cardiopathy and Nonstenosing Large Artery Plaque in Patients With Embolic Stroke of Undetermined Source. Stroke, 2020, 51, 938-943.	9.1	33
14	Carotid Plaque With High-Risk Features in Embolic Stroke of Undetermined Source. Stroke, 2020, 51, 311-314.	9.1	107
15	Intracranial and Systemic Atherosclerosis in the NAVIGATE ESUS Trial: Recurrent Stroke Risk and Response to Antithrombotic Therapy. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 104936.	2.2	20
16	Pharmacological Interventions for Asymptomatic Carotid Stenosis. Cochrane Database of Systematic Reviews, 2020, .	6.9	3
17	Aspirin and Low-Dose Rivaroxaban – The Dual Pathway Concept in Patients With Stable Atherosclerotic Disease: A Comprehensive Review. Expert Review of Cardiovascular Therapy, 2020, 18, 577-585.	2.7	3
18	Rivaroxaban for the Prevention of Major Adverse Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease. Future Cardiology, 2020, 16, 597-611.	1.2	2

#	Article	IF	Citations
19	New Horizons in Pharmacologic Therapy for Secondary Stroke Prevention. JAMA Neurology, 2020, 77, 1308-1317.	22.0	34
20	Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline. Stroke, 2020, 51, 2901-2909.	9.1	29
21	Rivaroxaban: A Review for Secondary CV Prevention in CAD and PAD. Drugs, 2020, 80, 1465-1475.	15.5	13
22	Ipsilateral Nonstenotic Carotid Disease in Minor Ischemic Stroke: An Exploratory Analysis of the POINT Randomized Clinical Trial. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 105115.	2.2	8
23	Stroke Prevention in Atrial Fibrillation. Circulation, 2020, 142, 2371-2388.	24.6	95
24	Effects of Rivaroxaban and Dabigatran on Local Expression of Coagulation and Inflammatory Factors Within Human Aortic Stenotic Valves. Vascular Pharmacology, 2020, 130, 106679.	3.4	17
25	Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland. Advances in Therapy, 2020, 37, 3348-3369.	5.0	9
26	Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source. Stroke, 2020, 51, 2139-2147.	9.1	7
27	Radiotherapy Is Associated With an Accelerated Risk of Ischemic Stroke in Oral Cavity Cancer Survivors After Primary Surgery. Cancers, 2020, 12, 616.	5.3	10
28	Dual Pathway Inhibition for Vascular Protection in Patients With Atherosclerotic Disease: Rationale and Review of the Evidence. Thrombosis and Haemostasis, 2020, 120, 1147-1158.	4.6	32
29	Antithrombotic Treatment in Patients With Stroke and Supracardiac Atherosclerosis. Neurology, 2020, 95, e499-e507.	5.0	10
30	Dual-Pathway Inhibition for Secondary and Tertiary Antithrombotic Prevention in Cardiovascular Disease. Nature Reviews Cardiology, 2020, 17, 242-257.	62.4	121
31	Embolic Stroke of Undetermined Source: JACC Review Topic of the Week. Journal of the American College of Cardiology, 2020, 75, 333-340.	12.0	248
32	Underlying Embolic and Pathologic Differentiation by Cerebral Microbleeds in Cryptogenic Stroke. Journal of Neurology, 2020, 267, 1482-1490.	5.4	10
33	Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome. CJC Open, 2020, 2, 402-415.	1.8	8
34	Prevalence, Predictors, and Prognosis of Symptomatic Intracranial Stenosis in Patients With Transient Ischaemic Attack or Minor Stroke: A Population-Based Cohort Study. Lancet Neurology, The, 2020, 19, 413-421.	43.7	149
35	Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial. Stroke, 2020, 51, 1797-1804.	9.1	74
36	Supracardiac Atherosclerosis in Embolic Stroke of Undetermined Source: The Underestimated Source. European Heart Journal, 2021, 42, 1789-1796.	14.7	53

#	Article	IF	Citations
37	Prevalence, Prognosis, and Treatment of Atherosclerotic Intracranial Stenosis in Caucasians. International Journal of Stroke, 2021, 16, 248-264.	7.4	27
38	Implementation and Management Outcomes of Pharmacogenetic CYP2C19 Testing for Clopidogrel Therapy in Clinical Practice. European Journal of Clinical Pharmacology, 2021, 77, 709-716.	3.8	18
39	High Thrombin Generation After Acute Ischemic Stroke or Transient Ischemic Attack Is Associated With a Reduced Risk of Recurrence: An Observational Cohort Study. Thrombosis and Haemostasis, 2021, 121, 584-593.	4.6	4
40	Patient-Tailored Antithrombotic Therapy Following Percutaneous Coronary Intervention. European Heart Journal, 2021, 42, 1038-1046.	14.7	39
41	Current Opportunities for Secondary Prevention of Atherothrombotic Stroke. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2021, 121, 97-105.	0.9	5
42	Новая эпоха антитромботической терапии в долгосрочной профилактике некардиоэмболического инсульта. Kardiologiya, 2021, 60, 97-103.	0.9	1
43	Use of Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention Across the Stroke Spectrum: Progress and Prospects. Thrombosis and Haemostasis, 2021, 121, 716-730.	4.6	5
44	Direct Oral Anticoagulants After Ischemic Stroke: Which Patient? Which Drug? And How Early?. Hamostaseologie, 2021, 41, 031-034.	1.5	1
45	Isoflurane Post-Conditioning Contributes to Anti-Apoptotic Effect After Cerebral Ischaemia in Rats Through the ERK5/MEF2D Signaling Pathway. Journal of Cellular and Molecular Medicine, 2021, 25, 3803-3815.	4.6	16
46	Особенности антитромботической терапии у пациентов с мультифокальным поражением артерий. Kardiologiya, 2021, 61, 87-95.	0.9	0
47	Co může internista udělat pro svého pacienta po ischemické cévní mozkové příhodě. Vnitrni Lekarstvi, 2021, 67, 7-14.	0.2	1
48	Embolischer Schlaganfall mit ungeklärter Emboliequelle (ESUS) – Klassifikation einer neuen Schlaganfallentität. Deutsche Medizinische Wochenschrift, 2021, 146, 403-409.	0.3	2
49	Antithrombotic Therapy in Patients With Coronary Artery Disease and Prior Stroke. Journal of Clinical Medicine, 2021, 10, 1923.	3.8	3
50	Криптогенный инсульт. Часть 1: аорто-артериальная эмболия. Meditsinskiy Sovet, 2021, 0, 78-87.	0.4	12
51	Silent Myocardial Infarction and Subsequent Ischemic Stroke in the Cardiovascular Health Study. Neurology, 2021, 97, e436-e443.	5.0	23
52	Features of Risk Stratification, Diagnosis and Secondary Prevention in Patients With Multifocal Arterial Disease. Part 2: Treatment Options. Rational Pharmacotherapy in Cardiology, 2021, 17, 239-248.	0.6	0
53	Chronic Coronary Syndrome: Overcoming Clinical Practice Guidelines. The Role of the COMPASS Strategy. Current Cardiology Reviews, 2021, 17, 294-305.	2.9	4
54	Considerations for Use of Direct Oral Anticoagulants in Arterial Disease. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12502.	3.3	3

#	Article	IF	Citations
55	Cardiovascular Consequences of Discontinuing Low-Dose Rivaroxaban in People With Chronic Coronary or Peripheral Artery Disease. Heart, 2021, 107, 1130-1137.	4.9	11
56	Canadian Stroke Best Practice Recommendations: Secondary Prevention of Stroke Update 2020. Canadian Journal of Neurological Sciences, 2022, 49, 315-337.	1.4	155
57	Clinical Efficacy and Safety Comparison of Rivaroxaban and Dabigatran for Nonvalvular Atrial Fibrillation Patients Undergoing Percutaneous Left Atrial Appendage Closure Operation. Frontiers in Pharmacology, 2021, 12, 614762.	5.3	11
58	Evolution of Evidence-Based Medicine in Stroke. Cerebrovascular Diseases, 2021, 50, 644-655.	2.1	2
59	Association of Major Adverse Cardiovascular Events in Patients With Stroke and Cardiac Wall Motion Abnormalities. Journal of the American Heart Association, 2021, 10, e020888.	5.8	15
60	Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial. Stroke, 2021, 52, 2494-2501.	9.1	23
61	The Impact of Dabigatran and Rivaroxaban on Variation of Platelet Activation Biomarkers and DRT Following Percutaneous Left Atrial Appendage Closure. Frontiers in Pharmacology, 2021, 12, 723905.	5.3	8
62	Non-Stenotic Carotid Plaques in Embolic Stroke of Unknown Source. Frontiers in Neurology, 2021, 12, 719329.	3.5	37
63	Prolonged Antithrombotic Therapy in Patients After Acute Coronary Syndrome: A Critical Appraisal of Current European Society of Cardiology Guidelines. Cardiology Journal, 2020, 27, 661-676.	1.7	11
64	Probabilistic Causal Model for the Detection of Obsolete Personal Information to Prevent Falls in the Elderly. Procedia Computer Science, 2021, 192, 1170-1179.	2.8	5
65	Thrombosis. , 2019, .		0
66	Atherothrombotic Stroke in Non-Valvular Atrial Fibrillation. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2019, 11, 78-81.	1.1	1
67	Residual Risk Reduction Opportunities in Patients With Chronic Coronary Syndrome. Role of Dual Pathway Inhibition. Expert Review of Clinical Pharmacology, 2020, 13, 695-706.	3.6	6
68	Does Prior Stroke Predict Long-Term Recurrent Stroke After Percutaneous Coronary Intervention? Five-Year Results From a Large Cohort Study. Frontiers in Neurology, 2021, 12, 740136.	3.5	2
69	New Possibilities of Antithrombotic Therapy Improving Prognosis in Patients With Stenosing Atherosclerosis of Carotid Arteries. Angiologiia I Sosudistaia Khirurgiia = Angiology and Vascular Surgery, 2020, 26, 17-21.	0.2	1
70	Combined Antithrombotic Therapy in Patients With a Stable Atherosclerotic Cardiovascular Diseases: What Direction Did COMPASS Show?. Kardiologiya, 2020, 60, 131-141.	0.9	0
71	Скрытые возможности профилактики ишемического инсульта у больных с заболеваниями, обусловленными атеросклерозом: результаты дополнительного анализа рандомизированных исследований ривароксабана. Russian Journal of Cardiology, 2020, 25, 3747.	1.9	1
72	Medical Management for Secondary Stroke Prevention. CONTINUUM Lifelong Learning in Neurology, 2020, 26, 435.	2.1	11

#	Article	IF	Citations
73	Direct Oral Anticoagulants Combined With Antiplatelet Therapy in the Treatment of Coronary Heart Disease: An Updated Meta-Analysis. Drugs, 2021, 81, 2003-2016.	15.5	7
74	Evolving Approaches to Antithrombotics in Stroke Prevention and Treatment. Southern Medical Journal, 2020, 113, 585-592.	0.7	0
75	Long-Term Outcomes of Coronary Artery Bypass Graft Surgery in Patients With Widespread Atherosclerotic Lesions of the Coronary and Peripheral Vascular Basins (Based on the REGATA Long-Term Antithrombotic Therapy Registry). Atherothrombosis, 2022, 11, 30-43.	0.5	5
76	Intracranial Atherosclerotic Stenosis: Risk Factors, Diagnosis, and Treatment. Lancet Neurology, The, 2022, 21, 355-368.	43.7	335
77	Dual Pathway of Inhibition and Vascular Protection in Patients With Atherosclerotic Disease. , 2021, .		0
78	Modern Strategies of Antithrombotic Therapy in Patients With Multifocal Atherosclerosis. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2022, 122, 49-55.	0.9	0
79	The Impact of Combination Therapy With Rivaroxaban and Acetylsalicylic Acid in Patients With Coronary Heart Disease on the Achievement of the Target for Reducing Mortality From Cardiovascular Diseases of the Federal Project "Fight Against Cardiovascular Diseases". Rational Pharmacotherapy in Cardiology, 2022, 18, 56-66.	0.6	1
80	Age Alters Prevalence of Left Atrial Enlargement and Nonstenotic Carotid Plaque in Embolic Stroke of Undetermined Source. Stroke, 2022, 53, 2260-2267.	9.1	11
81	Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists. Stroke, 2022, 53, 1813-1822.	9.1	73
82	Advances in Recurrent Stroke Prevention: Focus on Antithrombotic Therapies. Circulation Research, 2022, 130, 1075-1094.	15.7	28
83	Dual Antiplatelet Treatment for Minor Acute Ischemic Stroke and High-Risk Transient Ischemic Attack: Have We Reached the Limit of Antithrombotic Management?. European Journal of Internal Medicine, 2022, 100, 27-28.	4.2	1
84	COMPASS Study Results as a Foundation for New Treatment Approach for Neurological Patients. Opinion of the Expert Council of December 18, 2021. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2022, 122, 94-99.	0.9	2
85	European Stroke Organisation (ESO) Guideline on Pharmacological Interventions for Long-Term Secondary Prevention After Ischaemic Stroke or Transient Ischaemic Attack. European Stroke Journal, 2022, 7, I-II.	5.8	227
86	From Cryptogenic to ESUS: Toward Precision Medicine?. Revue Neurologique, 2022, 178, 939-952.	2.5	5
87	Carotid Artery Stenting: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 2022, 80, 155-170.	12.0	114
88	Management of Oral Anticoagulation and Antiplatelet Therapy in Post-Myocardial Infarction Patients With Acute Ischemic Stroke With and Without Atrial Fibrillation. Journal of Clinical Medicine, 2022, 11, 3894.	3.8	6
89	Low-Dose Aspirin for the Prevention of Atherothrombosis Across the Cardiovascular Risk Continuum. Cardiology Plus, 2022, 7, 64.	1.7	1
90	Managing Thrombotic Risk in Patients With Diabetes. Cardiovascular Diabetology, 2022, 21, 1-16.	15.7	19

#	Article	IF	Citations
91	Cancer-Related Stroke: Exploring Personalized Therapy Strategies. Brain and Behavior, 2022, 12, e2738.	3.1	21
92	Antiplatelet Therapy After Noncardioembolic Ischemic Stroke or Transient Ischemic Attack. Expert Review of Clinical Pharmacology, 2022, 15, 1027-1038.	3.6	5
93	Rationale and Design of the AXIOMATIC-SSP Phase II Trial: Antithrombotic Treatment With Factor XIa Inhibition to Optimize Management of Acute Thromboembolic Events for Secondary Stroke Prevention. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106742.	2.2	41
94	Carotid Stenosis and Stroke: Medicines, Stents, Surgery—"Wait-and-See" or Protect?. Thrombosis and Haemostasis, 2024, 124, 815-827.	4.6	21
95	Are Factor Xa Inhibitors Efficacious for Ischemic Stroke Prevention in Patients Without Atrial Fibrillation? Evidence From Randomized Clinical Trials. Canadian Journal of Cardiology, 2023, 39, 187-197.	3.8	1
96	Effects of Direct Oral Anticoagulants' Nonrecommended Dose in Atrial Fibrillation: A Meta-Analysis. European Neurology, 2023, 86, 13-24.	2.1	4
97	Prevalence and Overlap of Potential Embolic Sources in Embolic Stroke of Undetermined Source: A Retrospective Cohort. Emerging neurologist, 2022, 1, 16-24.	0.0	0
98	Российский консенсус по диагностике и лечению пациентов со стенозом сонных артерий. Russian Journal of Cardiology, 2022, 27, 5284.	1.9	50
99	Antiplatelet Therapy Aims and Strategies in Asian Patients With Acute Coronary Syndrome or Stable Coronary Artery Disease. Journal of Clinical Medicine, 2022, 11, 7440.	3.8	8
100	Chinese Expert Consensus on Antithrombotic Management of High-Risk Elderly Patients With Chronic Coronary Syndrome. Aging Medicine (Milton (N S W)), 2023, 6, 4-24.	3.2	4
101	Early Identification and Treatment for Peripheral Arterial Disease in Patients With Ischemic Cerebrovascular Disease. European Journal of Medical Research, 2023, 28, 1-7.	5.0	8
102	Der ischämische Schlaganfall. CME (Berlin, Germany), 2023, 20, 47-58.	0.0	0
103	Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions. Journal of Cardiovascular Development and Disease, 2023, 10, 164.	2.9	21
104	Comparative Effectiveness of Dual to Single Antiplatelet Therapy After One Year Versus Seven Years in Patients With Acute Ischemic Stroke Combined With Cerebral Microbleeds. Journal of Clinical Neuroscience, 2023, 112, 73-79.	2.1	1
105	Effect of the Frequency of Rehabilitation Treatments on the Long-Term Mortality of Stroke Survivors With Mild-to-Moderate Disabilities Under the Korean National Health Insurance Service System. Healthcare, 2023, 11, 1587.	4.1	3
106	Optimization of Secondary Prevention in Patients With High-Risk Atherothrombotic Ischemic Stroke or Transient Ischemic Attacks. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2023, 123, 36-43.	0.9	2
107	Patient With Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack. Part 2. Secondary Prophylaxis. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2023, 15, 4-10.	1.1	5
108	Risk of Recurrent Stroke in Patients With Atrial Fibrillation Treated With Oral Anticoagulants Alone or in Combination With Anti-Platelet Therapy. European Stroke Journal, 2023, 8, 722-730.	5.8	15

#	Article	IF	Citations
109	Pharmacological Interventions for Asymptomatic Carotid Stenosis. Cochrane Database of Systematic Reviews, 2023, 8, CD013573.	6.9	13
110	Efficacy and Safety of Oral Factor XIa Inhibitors in Stroke Prevention: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2023, 12, 5562.	3.8	17
111	Antithrombotic Treatment in Coronary Artery Disease. Current Pharmaceutical Design, 2023, 29, 2764-2779.	3.4	4
112	Consensus Statement for the Management of Incidentally Found Brain White Matter Hyperintensities in General Medical Practice. Medical Journal of Australia, 2023, 219, 278-284.	3.5	29
113	Mesenchymal Stem Cell-Derived Exosomes: A Novel Approach to Diabetes-Associated Cognitive Impairment. Journal of Inflammation Research, 2023, 16, 4213-4228.	4.6	7
114	Comparing Functional Outcomes and Safety Profiles of First-Line Aspiration Thrombectomy Versus Stentriever for Acute Basilar Artery Occlusion: Propensity Analysis of the PC-SEARCH Thrombectomy Registry. Stroke, 2023, 54, 2512-2521.	9.1	15
115	Safety of Tigecycline in Patients on Antithrombotic Therapy: A Single-Center Retrospective Study. Pharmacology, 2023, 108, 540-549.	2.5	4
116	Roundtable of Academia and Industry for Stroke Prevention: Prevention and Treatment of Large-Vessel Disease. Stroke, 2024, 55, 226-235.	9.1	4
117	Anticoagulants to Prevent Recurrent Non-Cardioembolic Stroke. Lancet Neurology, The, 2024, 23, 3-5.	43.7	0
118	Focused Update on Intracranial Atherosclerosis: Introduction, Highlights, and Knowledge Gaps. Stroke, 2024, 55, 305-310.	9.1	15
119	Optimal Medical Management of Atherosclerotic Intracranial Stenosis. Stroke, 2024, 55, 335-343.	9.1	20
120	Hemorrhagic Coagulation Disorders and Ischemic Stroke: How to Reconcile Both?. Neurology International, 2023, 15, 1443-1458.	3.9	8
121	Chinese Expert Consensus on Anti-Thrombotic Therapy for Pan-Vascular Diseases (2023 Edition). Cardiology Plus, 2024, 9, 49.	1.7	10
122	Rivaroxaban's Vascular Dose for the Neurovascular Clinician. Chinese Neurosurgical Journal, 2024, 10, 1-3.	1.5	0
123	Patient Acceptance and Adherence to the COMPASS Trial Drug Recommendations Following Symptomatic Carotid Endarterectomy. Annals of Vascular Surgery, 2024, 108, 403-409.	1.8	1
124	2024 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), With the Special Contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). European Heart Journal, 2024, 45, 3314-3414.	14.7	3,324
125	Risk of Stroke and Incident Atrial Fibrillation in Patients in Sinus Rhythm With Nonischemic Dilated Cardiomyopathy. American Journal of Cardiology, 2024, 233, 11-18.	2.4	3
126	Antithrombotic Therapy for Secondary Stroke Prevention in Patients With Symptomatic Large Artery Atherosclerosis and Atrial Fibrillation (FIB-CAS Study) a Single-Center Experience. Journal of the Neurological Sciences, 2025, 468, 123352.	2.7	6

#	Article	IF	Citations
127	Combination Antithrombotic Therapy for Reduction of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease. Stroke, 2025, 56, 380-389.	9.1	16
128	Integrated Care Management for Patients Following Acute Stroke: A Systematic Review. QJM - Monthly Journal of the Association of Physicians, 2025, 118, 317-328.	1.4	17
129	Beyond One-Size-Fits-All: Personalised 'Tailored' Approaches to Embolic Stroke of Undetermined Source. Journal of Stroke Medicine, 2024, 7, 103-113.	0.4	0
130	Efficacy and Safety of Addition of Oral Anticoagulant to Standard Antiplatelet Treatment in Patients With Ischemic Stroke and No Indication for Oral Anticoagulation: Systematic Review and Meta-Analysis. International Journal of Stroke, 2025, 20, 776-785.	7.4	4
131	A Nomogram Model Incorporating Blood Biomarkers Predicts 3-Week Functional Outcomes in Stroke Patients. Frontiers in Neuroscience, 2025, 19, 1609156.	4.2	2
132	Extended Dual Antithrombotic Therapy in Patients With Chronic Coronary Syndrome - Which Agent Should Be Added to Aspirin?. Cardiology Journal, 2025, 32, 321-327.	1.7	1
133	Prediction of Etiology and Prognosis Based on Hematoma Location of Spontaneous Intracerebral Hemorrhage: A Multicenter Diagnostic Study. Neuroradiology, 2025, 67, 1761-1772.	2.9	3
134	Secondary Stroke Prevention and Improvements in Acute Intracerebral Haemorrhage Care. International Journal of Stroke, 2025, 20, 772-775.	7.4	0
135	Carotid Artery Stenosis: A Guide for Clinicians. Future Cardiology, 2026, 22, 621-631.	1.2	0
136	Prognostic Value of the HELT-E2S2 Score in Patients With Lower Extremity Artery Disease and a Comparison With the Atrial Fibrillation and Lower Extremity Artery Disease Scores: Insight From the I-PAD NAGANO Registry. Journal of Atherosclerosis and Thrombosis, 2026, 33, 65783.	3.7	1
137	Switching From Aspirin Monotherapy After Noncardioembolic Stroke: A Systematic Review and Network Meta-Analysis. Stroke, 2026, 57, 650-661.	9.1	1
138	Rationale, Design and Baseline Characteristics of Participants in the OCEANIC-STROKE Trial of FXIa Inhibition for Secondary Stroke Prevention. European Stroke Journal, 2026, .	5.8	6
139	Chinese Guidelines for Diagnosis and Treatment of Intracranial Atherosclerotic Stenosis. International Journal of Stroke, 2026, 21, 1182-1195.	7.4	3
140	Peri-Stenotic Stagnation Associates With Red Blood Cell-Rich Thrombi, Linked to Stroke Recurrence and Lesion Volume. Stroke, 2026, 57, 908-922.	9.1	2
141	Low-Dose Rivaroxaban Plus Antiplatelet Therapy for Symptomatic Intracranial Atherosclerotic Stenosis: A Prospective Cohort Study. International Journal of Stroke, 2026, 21, 1130-1139.	7.4	2
142	Rationale for the Milvexian Dosing in the Phase 3 LIBREXIA Program. Journal of Thrombosis and Haemostasis, 2026, 24, 2158-2169.	5.0	12
143	Cerebrovascular Disease in Persons With Diabetes. , 2026, .		0
144	Antithrombotic Therapy for Noncardioembolic Ischemic Stroke: Current Evidence and Future Directions. Stroke, 2026, 57, 1439-1449.	9.1	5

#	Article	IF	Citations
145	Antithrombotic Strategies for the Secondary Prevention of Stroke: A Review. American Journal of Medicine, 2026, 139, 1118-1127.	3.2	0
146	Anticoagulation in Peripheral Artery Disease: Scoping Review With ❄SAIMSARA. , 2026, .		0
147	Asundexian for Noncardioembolic Ischemic Stroke. New England Journal of Medicine, 2026, 394, 1540-1541.	76.6	1
148	Asundexian for Secondary Stroke Prevention. New England Journal of Medicine, 2026, 394, 1467-1479.	76.6	56
149	Management of Large Artery Atherosclerosis. CONTINUUM Lifelong Learning in Neurology, 2026, 32, 869-885.	2.1	0
150	Early Post-Hospital Trajectories of Health-Related Quality of Life for Younger Adult Patients With Traumatic Brain Injury. Archives of Physical Medicine and Rehabilitation, 2026, .	3.0	0
151	The OCEANIC Trial Journey: From Failure to Breakthrough?. European Heart Journal - Cardiovascular Pharmacotherapy, 2026, 12, 349-352.	5.0	1
152	Left Ventricular Hypertrabeculation and Prognosis in Dilated Cardiomyopathy. Circulation, 2026, 154, 440-453.	24.6	2
153	NET-Mediated Immunothrombosis in Ischemic Stroke: Pathobiology, Biomarkers, and Therapeutic Targeting. Thrombosis Journal, 2026, 24, 80.	2.9	0
154	Antithrombotic Therapy for Secondary Prevention After Noncardioembolic Ischemic Stroke: Current Status, Limitations, and Future Directions. Thrombosis and Haemostasis, 2026, .	4.6	0
155	Factor XIa Inhibitors for Secondary Prevention After Noncardioembolic Stroke: A Systematic Review and Meta-Analysis. Neurology, 2026, 107, e218521.	5.0	0
156	Antithrombotic Therapy for Secondary Stroke Prevention in Patients With Symptomatic Large-Artery Atherosclerosis and Atrial Fibrillation: A Multicenter Experience. Journal of the American Heart Association, 2026, .	5.8	0
157	FXI and FXII in Experimental Stroke and FXI in Clinical Stroke Trials. Neurological Research and Practice, 2026, 8, 84.	3.3	0